The advancement of medical technology is dependent upon seemingly countless clinical studies and investigational testing. The safety of participants and the potential effectiveness of new technologies are always a primary concern. In order for research and testing to happen, particularly in the area of cancer treatment, a number of approvals must be in place to ensure the humane treatment of those volunteering. Theralase Technologies Inc. (TLT:CA) (TLTFF) is one such company going through the various approval channels in order to move forward with their innovative anti-cancer technology.
Theralase submitted an Investigational Testing Authorization (ITA) to Health Canada for approval of its anti-cancer technology, the Theralase TLC-3200 Oncology Laser System. The company’s submission of their ITA follows their recent announcement of a Clinical Trial Application. Theralase is also pending approval from the UHN Research Ethics Board.
One Step Closer to Cancer-Free
Detailed in Theralase’s ITA, by activating their Oncology Laser System with the company’s lead Photo Dynamic Compound (PDC), TLD-1433, the company plans to eliminate Non-Muscle Invasive Bladder Cancer (NMIBC). Each year in the United States, 50,000 men and 16,000 women are diagnosed with bladder cancer – making authorization approval of the Theralase TLC-3200 Oncology Laser System a pivotal moment in the fight against cancer.
“The submission of an ITA to Health Canada for NMIBC is yet another advancement for the Company in its quest to prove the safety, tolerability and efficacy of its anti-cancer technology in the destruction of NMIBC,” said Theralase’s President and CEO Roger Dumoulin-White. “Pending approval of the CTA, ITA and REB, UHN will commence enrolling and treating patients afflicted with this deadly disease.”
Theralase specializes in the design and manufacturing of laser technology that eliminates pain, accelerates tissue healing, and localizes cancer cells in order to accurately and completely eliminate them. Approval from these organizations will allow Theralase to conduct a crucial Phase Ib clinical study that will test the safety and tolerability of the anti-cancer technology on patients diagnosed with NMIBC.
For more information about Theralase’s medical research and development, visit www.theralase.com.
Disclosure: In the purview of Section 17(B) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention the fact that Equities.com, Inc. may be compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker, broker dealer, investment advisor, analyst, investment banker or underwriter. All profiles are based on information that is available to the public. The information contained herein should not be considered to be all-inclusive and is not guaranteed by Equities.com to be free from misstatement or errors. Readers are reminded to do their own due diligence when researching any companies mentioned on this website.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer